The Clorox Company (NYSE:CLX) Shares Sold by Northeast Investment Management

Northeast Investment Management trimmed its position in shares of The Clorox Company (NYSE:CLX - Free Report) by 4.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,547 shares of the company's stock after selling 2,677 shares during the quarter. Northeast Investment Management's holdings in Clorox were worth $7,590,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. CX Institutional grew its stake in Clorox by 4.8% in the 1st quarter. CX Institutional now owns 2,964 shares of the company's stock valued at $436,000 after acquiring an additional 136 shares during the period. Integrated Advisors Network LLC grew its holdings in shares of Clorox by 98.1% during the first quarter. Integrated Advisors Network LLC now owns 4,338 shares of the company's stock worth $639,000 after buying an additional 2,148 shares in the last quarter. Sonora Investment Management Group LLC raised its holdings in Clorox by 2.5% in the 1st quarter. Sonora Investment Management Group LLC now owns 2,940 shares of the company's stock valued at $433,000 after acquiring an additional 72 shares during the last quarter. Simplicity Wealth LLC acquired a new stake in Clorox in the 1st quarter valued at about $1,048,000. Finally, Wealthcare Advisory Partners LLC raised its holdings in Clorox by 47.8% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 2,350 shares of the company's stock valued at $346,000 after acquiring an additional 760 shares during the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Clorox Trading Down 3.3%

NYSE:CLX traded down $4.25 on Friday, reaching $123.03. 1,709,082 shares of the company's stock were exchanged, compared to its average volume of 1,361,693. The company has a quick ratio of 0.60, a current ratio of 0.94 and a debt-to-equity ratio of 20.52. The firm has a market capitalization of $15.16 billion, a price-to-earnings ratio of 33.61, a price-to-earnings-growth ratio of 2.62 and a beta of 0.54. The business has a fifty day moving average of $134.91 and a 200-day moving average of $148.35. The Clorox Company has a 52-week low of $122.84 and a 52-week high of $171.37.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). The business had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.74 billion. Clorox had a return on equity of 316.87% and a net margin of 6.38%. The firm's revenue for the quarter was down 8.0% on a year-over-year basis. During the same quarter last year, the company earned $1.71 earnings per share. As a group, analysts expect that The Clorox Company will post 7.15 earnings per share for the current year.

Wall Street Analyst Weigh In

CLX has been the subject of a number of recent research reports. Barclays cut their price objective on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a report on Wednesday, May 7th. JPMorgan Chase & Co. lowered their price target on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 6th. UBS Group lowered their price target on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Evercore ISI set a $140.00 price target on shares of Clorox and gave the company an "underperform" rating in a research report on Tuesday, May 6th. Finally, Morgan Stanley reduced their price objective on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $151.23.

Insider Buying and Selling

In other news, Director Pierre R. Breber bought 4,000 shares of the business's stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the purchase, the director now owns 4,000 shares of the company's stock, valued at approximately $546,280. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.57% of the company's stock.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.